

BUILDING ACCESS INTO PHARMACEUTICAL R&D AGREEMENTS: IDEAS AND POSSIBILITIES FROM REAL-WORLD CONTRACTS

BIOGRAPHIES OF SPEAKERS

JULIA BARNES-WEISE
Executive Director, The Global Health Innovation Alliance Accelerator (GHIAA)



Julia Barnes-Weise, J.D., CLP, Executive Director of the Global Healthcare Innovation Alliance Accelerator, cofounded the non-profit GHIAA in the spring of 2016 as a spin out of her work at Duke University as a Visiting Associate Professor of the Practice at Duke's Sanford School of Public Policy, and Director of the Sanford Innovation, Technology Policy project. The GHIAA MAPGuide, a guide to global health agreements, was launched in August 2020. Julia is a lawyer, board member, business development executive and Certified

Licensing Professional. She has been a Senior Business Development and Legal Consultant to the Coalition for Epidemic Preparedness Innovations (CEPI) for over three years. She was also a consultant on partnering for the Pandemic Preparedness Framework initiative of the WHO, during which time she co-authored a paper on the success and failures of the Ebola Outbreak 2014 consortia and created a system for monitoring potential Priority Pathogen development partner matching. She is a Collaborator with the Harvard University's Berkman Klein Center Global Access in Action initiative and is a frequent speaker on healthcare licensing and partnering. She is also a Consultant and Lecturer for the Duke Law School Access to Medicines course; and a Board Member of the Medical University of South Carolina Foundation for Research and Development. She is a former Director of Business Development at Glaxo Wellcome (now GSK), an attorney at SAS Institute and also founded and has consulted for BioMatch, LLC for many years. She has decades of experience negotiating IP licenses, alliance agreements and advising healthcare companies and institutions on partnering strategies. She has consulted with both US and European start-up companies and initiatives, including developing business development plans for venture capitalist backed spin out companies. Julia has a BA in Economics and Literature from Ohio Wesleyan University, a JD from the University of North Carolina at Chapel Hill, completed a yearlong Notre Dame University Law School programme on International Trade, and a course on International Marketing from the Duke University Executive Education programme at the Fugua School of Business.

DISCUSSANT

VIVIANA GALLI

Coordinator, European Alliance for Responsible R&D and Affordable Medicines



Since 2016 Viviana Galli coordinates the European Alliance for Responsible R&D and Affordable Medicines, an informal coalition of more than 60 patients, consumers and public health organisations across Europe. The Alliance is the first and only coalition of organisations in Europe working to call out and reduce the high prices of medicines, to promote public interest R&D financing and to foster new models of innovation. Viviana has extensive experience in civil society organisations and public interest advocacy. Before joining the access to

medicines field, she has been involved for several years in improving educational environments, fostering youth participation and representation and combating inequalities and discrimination. She holds a MA in European Studies from the University of Hamburg and a BA in Language and Cultural Mediation from the University of Milan.

MODERATOR

SUERIE MOONCo-Director, Global Health Centre, the Graduate Institute, Geneva



Suerie Moon, MPA, PhD, is Co-Director of the Global Health Centre and Visiting Lecturer at the Graduate Institute of International and Development Studies, Geneva. She also teaches and advises doctoral students at the Harvard T.H. Chan School of Public Health as adjunct Lecturer on Global Health. Her research and teaching focus on global governance, the political economy of global health (focusing on innovation and access to medicines; outbreak preparedness and response; trade, investment and intellectual property

rules; and development assistance for health), the evolution of international regimes, and innovative policies for addressing global problems. She is the author, with Wolfgang Hein, of *Informal Norms in Global Governance: Human Rights, Intellectual Property Rules, and Access to Medicines* (Routledge, 2013). She has conducted research on the policies and politics shaping innovation and access to medicines for twenty years, starting at Médecins Sans Frontières in 1999. She has served on a number of expert advisory bodies, including most recently the Board of Directors of the

Drugs for Neglected Diseases initiative, WHO Fair Pricing Forum Advisory Group, Expert Advisory Group to the UN Secretary General's High-Level Panel on Access to Medicines, Proposal Review Committee of UNITAID, and US National Academies of Medicine Forum on Antimicrobial Threats. Prior to joining the Graduate Institute, she was Study Director of the Harvard-LSHTM Independent Panel on the Global Response to Ebola, and co-founded and led the Forum on Global Governance for Health, a focal point at Harvard University for research, debate and strategic convening on issues at the intersection of global governance and health. She received a BA from Yale, an MPA from Princeton, and PhD from the Harvard Kennedy School of Government.